

# **Fluorescence tomography of red fluorescent protein expressed tumors in small animals**

**I. Turchin<sup>1</sup>, I. Fiks<sup>1</sup>, M. Kleshnin<sup>1</sup>, A. Orlova<sup>1</sup>, I. Balalaeva<sup>2</sup>,  
M. Shirmanova<sup>2,3</sup>, A. Rusanov<sup>4</sup>, S. Deyev<sup>5</sup>, A. Savitsky<sup>4</sup>**

*<sup>1</sup>Institute of Applied Physics of the RAS, Nizhny Novgorod, Russia*

*<sup>2</sup>Nizhny Novgorod State University, Russia*

*<sup>3</sup>Nizhny Novgorod State Medical Academy, Russia*

*<sup>4</sup>A.N. Bach Institute of Biochemistry of the RAS, Moscow, Russia*


*<sup>5</sup>Nizhny Novgorod State Medical Academy, Moscow, Russia*

# Whole-body fluorescence imaging techniques

- **Reflectance (epi-illumination) - 2D images**

Good transverse resolution for subcutaneous tumors


Very fast, no reconstruction



- **Transillumination (or Projection) method**

Visualisation of deep and subcutaneous tumors


Fast, no reconstruction




- **Fluorescent diffuse tomography (FDT) allows for 3D reconstruction of the fluorophore concentration**

Complicated,  
need for reconstruction.

Inverting matrix is big size,  
not sparse (unlike in CT),  
ill-conditioned






Diffuse pattern



# Whole-body fluorescent imaging applications

- Preclinical study of new photosensitizers for fluorescent diagnostics and photodynamic therapy.
- Visualization of the drug delivery process using fluorescent labels (quantum dots or fluorescent proteins).
- **Investigation of tumor growth, metastasis and retardation under therapy using tumor cells transfected with fluorescent proteins.**
- **Detection of molecular processes, in particular, fluorescence resonance energy transfer (FRET) in experimental animals.**



# FDT setup with a single source-detector pair

- **Projection method**


2D images, no reconstruction

*fluorescent proteins, photosensitizers, quantum dots*

- **Fluorescent diffuse tomography**

3D reconstruction if the fluorophore is well localized

*fluorescent proteins*





IV Turchin, AP Savitsky, et al. // JBO  
13, 041310 (2008)

# Algorithm of scanning an experimental animal

## projection method


obtaining a general view of the animal (source and detector are moving synchronously)




## 3D reconstruction

scanning of the selected region with small step sizes and different shifts between source and detector.


$d_x = -5 \text{ mm}$






$d_x = 0$






$d_x = 5 \text{ mm}$



$d_y = -5 \text{ mm}$




$d_y = 0$




$d_y = 5 \text{ mm}$


## Reconstructed distribution of fluorophore concentration




$z = 0 \text{ mm}$




$z = 1 \text{ mm}$



$z = 2 \text{ mm}$



$z = 3 \text{ mm}$





$z = 4 \text{ mm}$

# Algorithm of scanning an experimental animal


## projection method

obtaining a general view of the animal (source and detector are moving synchronously)




## 3D reconstruction

scanning of the selected region with small step sizes and different shifts between source and detector.





## Reconstructed distribution of fluorophore concentration





# Preclinical study of new photosensitizers for fluorescent diagnostics and photodynamic therapy (non-tomographic imaging)

Accumulation of “Photosens” (1 mg/kg, i.v.) in mouse cervical carcinoma



- Biodistribution
- Elimination
- Tumor selectivity
- Dosage studies

M.Shirmanova, IV Turchin, et al. // JBO, sent to publication

# Whole-body imaging of delivering fluorescent agents to the tumor (non-tomographic imaging)


Human breast carcinoma **SKBR-3** in nude mice

Intravenous injection of **Qdot 705 ITK** (Invitrogen Inc.),  
conjugated with **anti-HER2/neu 4D5 scFv-antibody**  
by barnase-barstar protein module


Ex 635 nm, Em<sub>max</sub> 705 nm

A.u.  
1500

100



before



1.5 hours after injection




Tumor  
nodes




# Investigation of tumor growth, metastasis and retardation under therapy using tumor cells transfected with fluorescent proteins

*DsRed2*




*TurboFP635*

(scientific name *Katushka*)




Larger wavelengths gives higher penetration depths.



# Intravital monitoring of tumor growth

Nude mice carrying human ovarian carcinoma SKOV-3 expressing Katushka



Scanning area


Control before tumor cells injection



15 days



19 days





22 days



# Algorithm of scanning an experimental animal

## projection method

obtaining a general view of the animal (source and detector are moving synchronously)






## 3D reconstruction

scanning of the selected region with small step sizes and different shifts between source and detector.




$d_x = -5 \text{ mm}$

$d_x = 0$




$d_x = 5 \text{ mm}$



$d_y = -5 \text{ mm}$




$d_y = 0$




$d_y = 5 \text{ mm}$


## Reconstructed distribution of fluorophore concentration




$z = 0 \text{ mm}$




$z = 1 \text{ mm}$



$z = 2 \text{ mm}$



$z = 3 \text{ mm}$



$z = 4 \text{ mm}$

# Direct Problem

Radiative transfer equation

$$(\vec{n}\nabla + \mu_a + \mu_s)L(\vec{r}, \vec{n}) = \frac{\mu_s}{4\pi} \iiint_{4\pi} L(\vec{r}, \vec{n}') \chi(\vec{n}, \vec{n}') d\Omega' + Q$$

$$E(\mathbf{r}) = \iiint_{4\pi} L(\vec{r}, \vec{n}) d\Omega$$

Analytical approximations

Numerical solution

*High accuracy,  
long time (hours)*

Monte Carlo method

Diffusive  
(at depth > 3-5 mm)

Small-angle  
(high anisotropic scattering)

Hybrid  
(at any depth)

$$E^{(diff)}(r) = \frac{3P\epsilon'}{4\pi} \frac{e^{-\sqrt{3\mu_a\mu_s'}r}}{r}$$

$$E^{(dir)}(\mathbf{r}_\perp, z) = \frac{P}{\pi a^2(z)} e^{-\mu_t' z - \frac{\mathbf{r}_\perp^2}{a^2(z)}}$$


$$E^{(gib)}(\vec{r}_1, \vec{r}_2, \lambda) = E^{(gdiff)}(\vec{r}_1, \vec{r}_2, \lambda) + E^{(gdir)}(\vec{r}_1, \vec{r}_2, \lambda)$$

Point -source field

Directional source field


# 3D reconstruction of the fluorophore concentration for plane geometries

Detectors ( $\lambda_{ex}$ ,  $\lambda_{em}$ )




Sources ( $\lambda_{ex}$ )

diffuse



hybrid model



# 3D reconstruction of the fluorophore concentration

System of linear equations:


$$P(\vec{r}_s, \vec{r}_d) = \iiint \Sigma_{object}(\vec{r}_0) P_{det}(\vec{r}_s, \vec{r}_d, \vec{r}_0) d\vec{r}_0 \quad \longrightarrow \quad A\mathbf{v} = \mathbf{p}$$

?

solution of direct problem

$$P_{det}(\vec{r}_s, \vec{r}_d, \vec{r}_0) = CE(\vec{r}_s, \vec{r}_0, \lambda_{ex})E(\vec{r}_0, \vec{r}_d, \lambda_{em})$$

Detector



$$\vec{r}_0 \rightarrow j$$

$$(\vec{r}_s, \vec{r}_d) \rightarrow i$$

$$\Sigma_{object}(\vec{r}_0) \rightarrow v_j$$


$$P(\vec{r}_s, \vec{r}_d) \rightarrow p_i$$

$$P_{det}(\vec{r}_s, \vec{r}_d, \vec{r}_0) \rightarrow A_{ij}$$

- Big size of matrix  $A$  (about  $10^8$  elements  $\sim$  1000 Mb Ram)
- Matrix  $A$  is not sparse (in comparison with CT)
- Matrix  $A$  matrix is ill-conditioned  $\sim 10^{13}$



## 3D reconstruction of the fluorophore distribution (at depth Z, object width is 1.2 cm)



## **Improving reconstruction of the fluorophore distribution:**

- Many source-detector measurements




  - using a sensitive CCD in order to reduce scanning time

- Additional information

  - time-domain or frequency-domain FDT


  - spectroscopic information

# FLUORESCENCE SPECTRUM ALLOWS TO LOCALIZE FLUORESCING TUMOR









The detected yellow/red intensity ratio as a function of the depth of the fluorescing layer in highly scattering medium ( $c$  – the contrast between the layer and the rest of the tissue model).

*J. Svensson and, S. Andersson-Engels, Opt. Express, v. 13, p. 4263 (2005)*



Spectral shape of fluorescence signal as a function of the fluorescence object position

# RESULTS OF IN VIVO EXPERIMENTS




*Fluorescence intensity for different scanning positions*

# *Reconstruction of the fluorophore spatial distribution*



Matrix coefficients

$$f_{i,j}(z_k, \lambda_m) = \frac{\gamma}{P_0} E(x_i, y_j, z_k, \lambda_0) E(x_i, y_j, d - z_k, \lambda_m)$$

defines the changes of fluorescence spectrum






*Fluorescence spectra registered from different depths in highly scattering medium (theoretical modeling)*



*M.Kleshnin, I. Turchin//  
Quantum Electronics,  
excepted for publication*

# *Reconstruction of the fluorophore spatial distribution*

*Nude mouse with RFP-expressing tumor*



*Plane images of fluorescent tumor corresponded to different depths of experimental animal*



# CCD-based FDT experimental setup


- **Fluorescent diffuse tomography**

3D reconstruction if the fluorophore is well localized *fluorescent proteins*


- **Backreflection for subcutaneous tumors**

2D images, no reconstruction



*fluorescent proteins, photosensitizers, quantum dots*




# Model experiment: reconstruction accuracy



# In-vivo experiment: RFP-expressing tumor in NUDE mouse




Back Reflection




3D reconstruction

- Inhomogeneity medium
- Autofluorescence
- Boundary condition

## 3D reconstruction of the DsRed2-expressing tumor in-vivo




# Investigation of molecular processes by whole-body fluorescence imaging (investigation of mechanism of drug effect) *Based on spectrum resolution*




Luo K.Q. *et al.* Biochemical and Biophysical Research Communications 304 (2003) 217–222

## *Based on life-time measurement*



## DFT setup using MCP-based ICCD




Fiber laser,  
wavelength 530 nm  
pulse duration <500 ps

Stanfordcomputeroptics ICCD  
Minimal gate time 200 ps  
Pulse repetition rate 200 kHz



Lifetime measurement  
provides separation of  
different fluorophores


Detection of molecular  
processes, in particular,  
fluorescence resonance  
energy transfer (FRET) in  
experimental animals *in vivo*.






# Results of the fluorescence imaging with lifetime resolution (mouse with the model of subcutaneous tumor expressing DsRed2)




Total fluorescence intensity



Approximation with  $\exp(-(t-t_0)/\tau)$




Calculated lifetime  $\tau$





## FLIM of the tumor, expressing TurboRFP (in a NUDE mouse)


Fluorescence intensity (in the maximum)



Fluorescence intensity (integrated in time)




Lifetime  $\tau$ , ns




# Fluorescence lifetime imaging for FRET (model experiment)

Fluorescence intensity  
(integrated in time)






Lifetime  $\tau$ , ns



FRET-pair

Testing medium



## **Conclusion**

**Fluorescence whole-body imaging allows for:**

- **Preclinical study of new photosensitizers for fluorescent diagnostics and photodynamic therapy.**
- **Visualization of the drug delivery process using fluorescent labels.**
- **Investigation of tumor growth under different conditions using fluorescent proteins (*3D reconstruction is available*).**
- **(*Potentially*) detection of FRET-processes *in vivo***



## **IAP, RAS**

I.V. Turchin

V.A. Kamensky

A.G. Orlova

N.M. Shakhova

M.Yu. Kirillin

M.S. Kleshnin

I.I. Fiks

V.I. Plehanov

V.A. Vorob'ev

M.B. Prudnikov

## **Acknowledgements**

This work was partly supported by the Russian Foundation for Basic Research (project #10-02-01109, # 07-02-01262) and the Science and Innovations Federal Russian Agency (project # 02.522.11.2002).



## Our collaborators

A.P. Savitsky, **INBI RAS**

I.G. Meerovich, **INBI RAS**

R.Rusanov, **INBI RAS**

I.V. Balalaeva, **NNSU**

A.A. Brilkina, **NNSU**

E.V. Zagaynova, **NNSMA RAMS**

M.V. Shirmanova, **NNSMA RAMS**

S.M. Deyev, **IBCH RAS**

T.A. Zdobnova, **IBCH RAS**